ESR2 and breast carcinoma: Using breast cancer cell lines, it was shown that estrogens have the ability to directly bind with GPR30 without ERα and ERβ involvement, alongside activating the ERK1/2 and mitogen-activated protein kinase (MAPK) pathways involved in the proliferation of various cells [159].